ICP
AKBA icon

Interchange Capital Partners’s Akebia Therapeutics AKBA Stock Holding History

Interchange Capital Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$2K – 254
2020
Q4 		$2K Buy
+1,000
New +$2.92K ﹤0.01% 1056

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Interchange Capital Partners's AKBA Position: Q1 2021 in Review

Interchange Capital Partners sold out of Akebia Therapeutics (AKBA) in Q1 2021, closing a stake of 1,000 shares — an estimated $2K sold.

Interchange Capital Partners first reported a position in AKBA in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 145 funds tracked by Wall St. Rank hold AKBA as of Q1 2021.

  • Interchange Capital Partners reported no remaining Akebia Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Interchange Capital Partners sold 1,000 Akebia Therapeutics shares in Q1 2021, an estimated $2K.
  • Interchange Capital Partners first reported a position in Akebia Therapeutics in Q4 2020 and held it in 1 quarter.
  • Interchange Capital Partners's Akebia Therapeutics position peaked at $2K in Q4 2020.
  • 145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2021.

Based on Interchange Capital Partners's 13F filing for Q1 2021, filed 5 May 2021.